Incyte Corporation last reported quarterly results on Oct 29, 2026, for Q3 FY2026 (the quarter ended Sep 30, 2026): revenue of $1.6 billion (+14.0% year over year) and diluted EPS of -$3.86. It usually reports 28–41 days after a quarter ends. Based on that pattern, the next release is estimated for around Feb 9, 2027.
Results for Q4 FY2026, the quarter ending around Dec 31, 2026. Expected on a Tuesday. Based on last year's release for the same quarter on Feb 10, 2026. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 28–41 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Oct 29, 2026
29 days after quarter end
|
Q3 FY2026
ended Sep 30, 2026
|
1,557
+14.0%
|
-785
-285.0%
|
-3.86
-282.9%
|
|
Jul 28, 2026
28 days after quarter end
|
Q2 FY2026
ended Jun 30, 2026
|
1,674
+37.7%
|
586
+44.6%
|
2.81
+37.7%
|
|
Apr 28, 2026
28 days after quarter end
|
Q1 FY2026
ended Mar 31, 2026
|
1,273
+20.9%
|
303
+91.7%
|
1.47
+83.7%
|
|
Feb 10, 2026
41 days after quarter end
|
Q4 FY2025
ended Dec 31, 2025
|
1,507
+27.8%
|
299
+48.7%
|
1.46
+50.4%
|
|
Oct 28, 2025
28 days after quarter end
|
Q3 FY2025
ended Sep 30, 2025
|
1,366
+20.0%
|
424
+298.4%
|
2.11
+290.7%
|
|
Jul 29, 2025
29 days after quarter end
|
Q2 FY2025
ended Jun 30, 2025
|
1,216
+16.5%
|
405
+191.1%
|
2.04
+200.0%
|
|
Apr 29, 2025
29 days after quarter end
|
Q1 FY2025
ended Mar 31, 2025
|
1,053
+19.5%
|
158
-6.7%
|
0.80
+6.7%
|
|
Feb 10, 2025
41 days after quarter end
|
Q4 FY2024
ended Dec 31, 2024
|
1,179
+16.3%
|
201
+0.1%
|
0.97
+9.5%
|
Company profile
- Industry
- Services-Commercial Physical & Biological Research (SIC 8731)
- Listed as
- INCY (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Wilmington, DE
- SEC filer status
- Large accelerated filer
- SEC CIK
- 879169
- Former names
- INCYTE INC (until Mar 28, 2003); INCYTE GENOMICS INC (until Feb 25, 2003); INCYTE PHARMACEUTICALS INC (until Apr 18, 2000)
Other Services-Commercial Physical & Biological Research companies
- Iqvia Holdings Inc. IQV
- Medpace Holdings, Inc. MEDP
- Charles River Laboratories International, Inc. CRL
- Icon PLC ICLR
- Absci Corp ABSI
- OmniAb, Inc. OABI
- NRC Health NRC
- Maxcyte, Inc. MXCT
All 17 Services-Commercial Physical & Biological Research companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.